Drug intelligence / Profile preview

XOB

Development stage: Unknown
Lead developer: Alexander Shulgin Research Institute
Modality: Small Molecules

Overview

XOB is a synthetic compound known chemically as N-[(4-phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine. It acts as a serotonin 5-HT2A receptor antagonist and also blocks voltage-gated sodium channels. These dual actions suggest potential effects on both neurotransmission and neuronal excitability, but there is no evidence of clinical development or approved medical use for this compound. Its primary relevance appears to be in research settings related to neuropharmacology[1].

Other names: N-[(4-phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine

Targets

NaV (Voltage-gated sodium channels)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on XOB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XOB.

Explore the full profile